Saturday, July 11, 2026

pharma · Systemic Lupus Erythematosus

Santhera Pharmaceuticals Holding

Santhera Pharmaceuticals Holding clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Pratteln, CH HQ
2004 Founded
115 Employees
EMA registrant Type
Company details
Status
Public
HQ
Pratteln, CH
Founded
2004
Employees
115
Programs
2
Drugs
1
Patents
0
Intelligence · Clinical Programs

Santhera Pharmaceuticals Holding projects

1 ClinicalTrials.gov programs sponsored by Santhera Pharmaceuticals Holding.

Santhera Pharmaceuticals Holding has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. blisibimod

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Santhera Pharmaceuticals Holding have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.